Vericel Corporation Third Quarter 2026 - VERICEL CORP

Financial Performance:

• Total Q3 2026 revenue reached a record $85.4 million, a 26% year-over-year increase, significantly exceeding guidance.
• Macy segment generated $67.4 million in revenue (+21% YoY), marking the sixth consecutive quarter of 20%+ growth.
• Burn Care segment posted record revenue of $18 million (+52% YoY), with EpiCell at $12.7 million (+23%) and Nexabrid commercial revenue at $2.3 million (+54%).
• GAAP net income surged 179% to $14.2 million ($0.27/share); Adjusted EBITDA grew 48% to $25.2 million.
• Adjusted EBITDA margin expanded to 30% (up from ~25% prior year), with gross margins exceeding 73%.
• Free cash flow for the quarter was $16 million, with YTD FCF exceeding $45 million; ending Q3 with $236 million in cash and zero debt.
• Company repurchased 221,000 shares for $8.8 million, leaving $191 million under authorization.

Guidance and Future Outlook:

• Full-year 2026 total revenue guidance raised to $344–$346 million (midpoint $345M), representing 25% growth and an increase of ~$25M from year-start guidance.
• Macy full-year guidance raised to $290–$292 million; Q4 Macy revenue guidance increased to ~$102 million (21% growth), with potential for upside if Q4 trends continue.
• Burn Care full-year guidance raised to ~$54 million (from $46–$50M), implying $12M in Q4 ($9M commercial + $3M barter).
• Full-year Adjusted EBITDA margin guidance raised to ~28% (from 27%); Gross margin expected to remain ~75%.
• Long-term growth drivers include UK launch (H2 2027), potential ankle indication, and continued commercial excellence initiatives targeting sustained 20%+ growth in 2027.

Business Segments and Product Lines:

• Macy: Strong momentum driven by sales force expansion, increased biopsies per surgeon, and rising adoption of Macy-Arthro (25% of condyle defects <4cm treated arthroscopically).
• Macy-Arthro: Record number of procedures and surgeons; new clinical publications highlight durable outcomes and faster recovery, supporting expansion into smaller defect sizes and patella regions.
• Burn Care: EpiCell growth driven by increased biopsying centers and cross-selling with Nexabrid; Nexabrid saw record ordering centers (80+ total, 70+ repeat users).
• UK Expansion: MHRA inspection complete; NICE accepted Macy for single technology appraisal to establish reimbursement; manufacturing facility upgraded.
• Innovation: Next-generation Macy-Arthro instruments under development to simplify procedures and expand access to patella defects.

Market and Competitive Landscape:

• Macy maintains clear market leadership in autologous chondrocyte implantation (ACI) with a 10-year track record; market described as large, underpenetrated, and shifting toward restorative therapies.
• Competitive landscape in UK/Europe viewed as stable for Macy, with surgeons viewing ACI as gold standard and demographic/physician preferences remaining consistent with US launch.
• Commercial excellence initiatives (rebranding, peer-to-peer programs, training labs) have tripled engagement; new territories showing highest biopsy growth rates.
• Consensus revenue estimates for 2027 align with internal expectations, serving as a conservative baseline for guidance.

Risks and Challenges:

• Burn care volume remains contingent on external factors (number of catastrophic burn incidents and patient survival rates), though execution capabilities are deemed repeatable.
• Ongoing investment in manufacturing, sales force expansion, and international launch (UK/Canada) creates near-term spending headwinds, though margins continue to expand.
• Revenue guidance reflects a conservative philosophy at year-start, with management reserving flexibility for upside as momentum solidifies.

Management Commentary and Tone:

• Management expressed high confidence ("bullish") regarding 2027 prospects, citing strong execution, commercial momentum, and alignment with long-term revenue targets.
• Tone was emphatic on the inflection of profitability and cash flow, noting Q3 as the strongest quarter of the year on multiple metrics.
• Executives maintained a disciplined approach to guidance, opting to raise ranges incrementally based on visible momentum rather than over-promising on uncertain long-term variables.

Analyst Questions and Answers:

• LRP Targets: CFO Joe Marra confirmed the company is on track to hit midterm long-range plan (LRP) targets; no immediate updates to LRP numbers anticipated as internal progress exceeds expectations.
• Salesforce Productivity: Nick Colangelo noted new rep territories are leading biopsy growth, with historical data suggesting 2nd/3rd-year reps will drive subsequent implant growth in 2027+.
• Surgeon Penetration: Growth is balanced between adding new surgeons and increasing biopsies per existing surgeon; Macy-Arthro implanter adoption correlates with higher overall utilization across defect sizes.
• 2027 Guidance: Management intends to start 2027 guidance conservatively (likely ~20% base) but expects to outperform internally driven targets throughout the year.
• Margin Trajectory: Margins expected to expand further in 2027+ driven by leverage, manufacturing utilization, and Salesforce scale, potentially reaching high 30% range long-term.
• BART Agreement: Expected to contribute ~$3M in Q4 2026, ~$4M in Q1 2027, with additional procurement revenue opportunities later in the year; development cost offsets also impacting P&L.
• Capital Allocation: With $236M cash and no debt, management sees no conflict between share buybacks and strategic M&A (BD), positioning the firm to pursue opportunistic transactions.

Other Key Points:

• Macy-Arthro adoption is increasing across various knee compartments (trochlea, condyle), not limited to previous primary segments.
• Cross-selling strategy between EpiCell and Nexabrid has been pivotal in driving record Burn Care performance.
• The company has completed annual ATU (Awareness, Trial, Usage) market research reinforcing Macy's leader positioning among surgeons.
• Clinical data from outside the US supports 13.6-year durability and high patient satisfaction for arthroscopic Macy procedures.